Biovica International AB (publ) (BIOVIC_B) Q3 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone, and welcome to our earnings call for the third quarter of our fiscal year. Today, it will be me and our CFO, Anders Morian, will do the presentation. And the agenda will be first a short introduction about Biovica. We'll go through the highlights, then Anders will go through the financials, and then we'll end with a summary and a Q and A session. The Q and A session will be done this way that we will have Filipe Lindfist, our analyst from Redeye, into the call asking questions, but you can also submit questions that will be answered in writing and appended to the presentation that will be put on our homepage after the call. So I'll start with Biovica and our product Divatum. Divatum measures what's the core of cancer, which is self proliferation, and the way we do it is through a blood sample from the patient that is analyzed using our assay in our lab or in an external lab. And by doing so, you will get a precise understanding how the tumours are proliferating, which is an indication of how aggressive the disease is, which is of course is important when making treatment decisions. Also, it has proven to be an excellent tool for monitoring of treatments and to get feedback over time and get quick feedback earlier and then with other methods like imaging. This has been proved in several clinical trials. We have more than 30 peer reviewed articles and that has been studies that have been performed with some of the leading oncologists in the business at some of the most well renowned institutions and like John Hopkins, Washington U, Mayo Clinic, etc. And the majority of these trials are within our first application, the breast cancer area, although there are potential also outside to expand into other large area where the DIVITUM can add benefits both to...